Goodridge, Jodie P.
Jacobs, Benedikt
Saetersmoen, Michelle L.
Clement, Dennis
Hammer, Quirin http://orcid.org/0000-0003-2968-6061
Clancy, Trevor http://orcid.org/0000-0001-9896-0613
Skarpen, Ellen
Brech, Andreas
Landskron, Johannes
Grimm, Christian
Pfefferle, Aline
Meza-Zepeda, Leonardo http://orcid.org/0000-0003-3056-212X
Lorenz, Susanne
Wiiger, Merete Thune
Louch, William E.
Ask, Eivind Heggernes http://orcid.org/0000-0001-8655-1433
Liu, Lisa L.
Oei, Vincent Yi Sheng http://orcid.org/0000-0002-9336-529X
Kjällquist, Una
Linnarsson, Sten http://orcid.org/0000-0002-3491-3444
Patel, Sandip
Taskén, Kjetil
Stenmark, Harald
Malmberg, Karl-Johan http://orcid.org/0000-0002-8718-9373
Article History
Received: 9 July 2018
Accepted: 4 January 2019
First Online: 31 January 2019
Competing interests
: K.J. Malmberg is a scientific advisor and consultant at Fate Therapeutics. J.P. Goodridge is currently employed as a Scientist at Fate Therapeutics (started after completion of this work). Malmberg and Goodridge are co-inventors on a patent application concerning the use of lysosomal modulation to tune NK and T cell function. The other authors declare no competing interests.